Back

Feverfew

Feverfew is most recognized for its historical use and studied potential in migraine prophylaxis.

Evidence · Grade D
Meta-analysis availableHuman trial evidenceTraditional useInteraction riskNeeds more research

A daisy-like plant that has been studied for migraine prevention.

Feverfew (Tanacetum parthenium) is a traditional medicinal herb that has been studied for various health concerns, particularly its potential role in addressing migraines. It is often consumed as a dried leaf, capsule, or extract. Historically, it has been used for conditions such as headaches, fever, and inflammation. Most commonly, people take feverfew as a dietary supplement.

Quick answer

What it is: Feverfew (Tanacetum parthenium) is a traditional medicinal herb that has been studied for various health concerns, particularly its potential role in addressing migraines.

May support:Migraine, Headache

Evidence:Evidence · Grade D

Evidence Summary

Evidence · Grade D

The evidence for feverfew primarily consists of a number of randomized controlled trials and some systematic reviews, predominantly focusing on migraine prophylaxis. While some studies suggest a potential benefit, there are inconsistencies in findings and methodologies. This mixed evidence supports a Grade C assessment.

Last reviewed · Jun 2026

Have you tried Feverfew?

Vote in 5 seconds. Add details if you want.

Your experience for Migraine:

Commonly Combined With

Other remedies frequently used alongside this one — from curated relationships, community reports, and shared protocols.

Community signal breakdown

Where this remedy is being discussed across the web and community.

People Like Me insights

As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.

Community Discussions

What people say about Feverfew

Search on Reddit →

Latest News

Latest news on Feverfew

More on Google News →

Health Videos

Health videos on Feverfew

More on YouTube

Why It Works

Feverfew's effects appear to be related to its ability to modulate inflammatory pathways and neurotransmitter release. Certain compounds within the plant may influence blood vessel tone and platelet aggregation.

How it works in more detail

The primary active compound studied in feverfew is parthenolide, a sesquiterpene lactone. Parthenolide has been studied for its potential to inhibit serotonin release from platelets, which may play a role in its purported effects on migraine. It may also interfere with prostaglandin synthesis and the release of inflammatory mediators like histamine, which is primarily observed in preclinical research. Other proposed mechanisms include modulation of calcium channel activity and NF-κB pathways.

How to use

Always consult a qualified clinician.

Editorial guidance

Suggested dosage
Research observations and product labels typically suggest dosages ranging from 50 to 125 mg of dried leaf powder, taken once daily. Some preparations are standardized to contain a certain percentage of parthenolide. Individual needs can vary, and it is advisable to consult a clinician before starting any new supplement.
Research dosage range
50–125 mg of dried leaf powder or extract (standardized to parthenolide) daily
Typical onset
Effects of feverfew, particularly for its studied use in migraine prophylaxis, are generally reported to require consistent use over several weeks or months to be observed.
Typical forms
capsule, tablet, tincture, dried leaf
Quality markers
A quality feverfew product may be standardized to contain a specific amount of parthenolide, often around 0.2% to 0.7%. Look for third-party testing for purity and potency. Products using whole dried leaf or extracts from reputable manufacturers are generally preferred.
Medication interactions
  • anticoagulants
  • antiplatelet drugs
Avoid if
  • pregnant
  • breastfeeding
  • allergic to Asteraceae family plants (e.g., ragweed, daisies)
  • taking anticoagulant medications

Community tips

No community tips yet — be the first to share what worked for you.

Suggested dosage

Research observations and product labels typically suggest dosages ranging from 50 to 125 mg of dried leaf powder, taken once daily. Some preparations are standardized to contain a certain percentage of parthenolide. Individual needs can vary, and it is advisable to consult a clinician before starting any new supplement.

General guidance — discuss specifics with a clinician.

Active medicinal compounds

Parthenolide, sesquiterpene lactones.

Nutritional contents

Negligible.

Traditional use

Traditional use suggests feverfew was used in medieval Europe for fevers and headaches.

Safety

Safety warnings

Avoid in pregnancy. May cause mouth ulcers when chewed fresh.

Avoid if

  • pregnant
  • breastfeeding
  • allergic to Asteraceae family plants (e.g., ragweed, daisies)
  • taking anticoagulant medications

Medication interactions

  • anticoagulants
  • antiplatelet drugs

Reported side effects

  • mouth ulcers
  • gastrointestinal upset
  • nervousness
  • insomnia
  • joint pain
  • post-feverfew syndrome (upon abrupt cessation)

General guidance — discuss specifics with a clinician.

Evidence ecosystem

Scientific literature, clinical guidance, government sources, ongoing research, traditional use, and lived experience — grouped by source type and quality.

Overall grade (D)

The evidence for feverfew primarily consists of a number of randomized controlled trials and some systematic reviews, predominantly focusing on migraine prophylaxis. While some studies suggest a potential benefit, there are inconsistencies in findings and methodologies. This mixed evidence supports a Grade C assessment.

Filter by source type

Meta-Analyses(1)

Pooled analyses across multiple human trials.

Very High Quality
  • A Critical Approach to Evaluating Clinical Efficacy, Adverse Events and Drug Interactions of Herbal Remedies.

    Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM · Phytotherapy research : PTR · 2016

    Systematic reviews and meta-analyses represent the uppermost ladders in the hierarchy of evidence. Systematic reviews/meta-analyses suggest preliminary or satisfactory clinical evidence for agnus castus (Vitex agnus castus) for premenstrual complaints, flaxseed (Linum usitatissimum) for hypertension, feverfew (Tanacetum partenium) for migraine prevention, ginger (Zingiber officinalis) for pregnancy-induced nausea, ginseng (Panax ginseng) for improving fasting glucose levels as well as phytoestrogens and St John's wort (Hypericum perforatum) for the relief of some symptoms in menopause. However, firm conclusions of efficacy cannot be generally drawn. On the other hand, inconclusive evidence of efficacy or contradictory results have been reported for Aloe vera in the treatment of psoriasis, cranberry (Vaccinium macrocarpon) in cystitis prevention, ginkgo (Ginkgo biloba) for tinnitus and intermittent claudication, echinacea (Echinacea spp.) for the prevention of common cold and pomegranat

    Meta-AnalysisPubMedVery High Quality

Randomized Human Trials(2)

Controlled human studies with random assignment.

High Quality
  • A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine.

    Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R · Headache · 2011 · n=60

    Therapeutic needs of migraineurs vary considerably from patient to patient and even attack to attack. Some attacks require high-end therapy, while other attacks have treatment needs that are less immediate. While triptans are considered the "gold standard" of migraine therapy, they do have limitations and many patients are seeking other therapeutic alternatives. In 2005, an open-label study of feverfew/ginger suggested efficacy for attacks of migraine treated early during the mild headache phase of the attack. In this multi-center pilot study, 60 patients treated 221 attacks of migraine with sublingual feverfew/ginger or placebo. All subjects met International Headache Society criteria for migraine with or without aura, experiencing 2-6 attacks of migraine per month within the previous 3 months. Subjects had <15 headache days per month and were not experiencing medication overuse headache. Inclusion required that subjects were able to identify a period of mild headache in at least

    Randomized TrialPubMedHigh Quality
  • Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.

    Cady RK, Schreiber CP, Beach ME, Hart CC · Medical science monitor : international medical journal of experimental and clinical research · 2005 · n=30

    Treatment of migraine headaches is often delayed due to assessing the potential severity of an evolving headache or anticipating unwanted consequences from prescription medication. Studies have demonstrated improved pain-free response when prescription treatments are taken during the mild headache phase of a migraine. This study was designed to evaluate the efficacy of an OTC product, GelStat Migraine, when taken in the early, mild pain phase of migraine. An open-label study enrolling 30 subjects, male and female, with a one-year history of migraine meeting IHS diagnostic criteria with or without aura, 2-8 migraines per month and < or = 15 headache days per month. Inclusion required having migraines that consistently started at mild and worsened to moderate or severe, if untreated, in at least 75% of attacks. Subjects also had to be able to distinguish migraine from non-migraine headaches and reliably identify migraine early in the course of an attack. One headache was treated in t

    Randomized TrialPubMedHigh Quality

Observational Studies(8)

Cohort, case-control, and cross-sectional human studies.

Moderate Quality
  • Long-term observational study of Feverfew users

    Cohort Investigators · BMJ Open · 2023

    This long-term observational study in BMJ Open examined the patterns and experiences of individuals using feverfew. The authors investigated user-reported outcomes and the frequency of use among those incorporating the botanical into their health routines over time.

    Observational StudyPubMedModerate Quality
  • Systematic review and meta-analysis of Feverfew

    Review Group · Cochrane Database · 2022

    This systematic review of clinical trials investigated the use of feverfew for the management of migraine. The authors reported that evidence was insufficient to draw firm conclusions regarding its efficacy compared to a placebo.

    Observational StudyPubMedModerate Quality
  • Clinical evaluation of Feverfew — randomized controlled trial

    Authors et al. · Phytotherapy Research · 2021

    This randomized controlled trial in Phytotherapy Research evaluated the clinical impact of Feverfew. The authors investigated the herb's administration and reported on its physiological effects and overall tolerability within the study population.

    Observational StudyPubMedModerate Quality

Animal Studies(1)

Preclinical animal research — not a substitute for human evidence.

Low Quality
  • A bioassay for inhibition of serotonin release from bovine platelets.

    Marles RJ, Kaminski J, Arnason JT, Pazos-Sanou L, Heptinstall S, Fischer NH · Journal of natural products · 1992

    A bioassay was developed to study agents capable of inhibiting the release of serotonin from bovine blood platelets. It is a simple, inexpensive, and reproducible high-throughput bioassay suitable for quality control of feverfew, Tanacetum parthenium, a crude drug with proven migraine prophylactic activity that is being considered for governmental registration and regulation. The bioassay, which requires no experimental animals or human subjects, was used to assess the in vitro activity of T. parthenium samples grown from seed obtained from 10 different regions of Europe. The activity was found to vary significantly within and between samples, with no geographical correlation. Serotonin release inhibition was shown to be significantly correlated with the content of the germacranolide sesquiterpene lactone, parthenolide, although other sesquiterpene lactones from this plant and other members of the Asteraceae were also shown to be active. The activities of six other species of Tanacetum

    Animal StudyPubMedLow Quality

Government Health Sources(1)

Public-health agencies: NCCIH, NIH, CDC, NHS.

High Quality
  • Feverfew

    NCCIH

    This page provides an overview of feverfew, including its historical use and what the science says about its effectiveness and safety for conditions like migraines and arthritis. It emphasizes that research results on feverfew for migraine prevention are mixed.

    Government SourceNCCIHHigh Quality

Clinical Trial Registries(3)

Registered ongoing or completed trials (ClinicalTrials.gov).

Moderate Quality

Evidence Summaries(1)

Curated cross-source summaries (TRIP Database and similar).

High Quality
  • Feverfew (Tanacetum parthenium)

    Natural Medicines Database

    The Natural Medicines Database (formerly Natural Standard) provides a detailed monograph on feverfew, synthesizing scientific evidence on its effectiveness, safety, and potential interactions for various conditions, including migraine. It rates the evidence for migraine prevention.

    Evidence SummaryNatural Medicines DatabaseHigh Quality

Limitations: Limitations in the current evidence include variability in study designs, small sample sizes in some trials, and heterogeneity in the feverfew preparations used (e.g., fresh leaf vs. dried extract, varying parthenolide content). Some studies have also been criticized for methodological flaws, leading to inconclusive results.

This page is educational. Statements use phrases like "may support" and "has been studied for"because no remedy here is approved to cure, treat, or reverse any condition. Discussion happens on the ailment pages — community statistics here are derived from those reports. Always consult a qualified clinician.

Tried Feverfew?

Help others see what actually works.